Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study

Hertzel C Gerstein; Sibylle Hess; Brian Claggett; Kenneth Dickstein; Lars Kober; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Jean-Claude Tardif; Marc A Pfeffer

doi:10.2337/dc22-0453

Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study

Hertzel C Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Kober, Aldo P Maggioni, John J V McMurray, Jeffrey L Probstfield, Matthew C Riddle, Jean-Claude Tardif, Marc A Pfeffer

Afdeling for Hjertesygdomme

5 Citationer (Scopus)

Abstract

OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death.

RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel.

RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively.

CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP's prognostic value.

Originalsprog	Engelsk
Tidsskrift	Diabetes Care
Vol/bind	45
Udgave nummer	9
Sider (fra-til)	2152-2155
Antal sider	4
ISSN	1935-5548
DOI	https://doi.org/10.2337/dc22-0453
Status	Udgivet - 1 sep. 2022

Adgang til dokumentet

10.2337/dc22-0453

Andre filer og links

Link to publication in Scopus

Citationsformater

Gerstein, H. C., Hess, S., Claggett, B., Dickstein, K., Kober, L., Maggioni, A. P., McMurray, J. J. V., Probstfield, J. L., Riddle, M. C., Tardif, J.-C., & Pfeffer, M. A. (2022). Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. Diabetes Care, 45(9), 2152-2155. https://doi.org/10.2337/dc22-0453

@article{af9e915fe2fd48dcb5e4b065995679a4,

title = "Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study",

abstract = "OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death.RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel.RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively.CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP's prognostic value.",

author = "Gerstein, {Hertzel C} and Sibylle Hess and Brian Claggett and Kenneth Dickstein and Lars Kober and Maggioni, {Aldo P} and McMurray, {John J V} and Probstfield, {Jeffrey L} and Riddle, {Matthew C} and Jean-Claude Tardif and Pfeffer, {Marc A}",

note = "{\textcopyright} 2022 by the American Diabetes Association.",

year = "2022",

month = sep,

day = "1",

doi = "10.2337/dc22-0453",

language = "English",

volume = "45",

pages = "2152--2155",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association",

number = "9",

}

TY - JOUR

T1 - Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome

T2 - The ELIXA Biomarker Study

AU - Gerstein, Hertzel C

AU - Hess, Sibylle

AU - Claggett, Brian

AU - Dickstein, Kenneth

AU - Kober, Lars

AU - Maggioni, Aldo P

AU - McMurray, John J V

AU - Probstfield, Jeffrey L

AU - Riddle, Matthew C

AU - Tardif, Jean-Claude

AU - Pfeffer, Marc A

PY - 2022/9/1

Y1 - 2022/9/1

N2 - OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death.RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel.RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively.CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP's prognostic value.

AB - OBJECTIVE: To use protein biomarkers to identify people with type 2 diabetes at high risk of cardiovascular outcomes and death.RESEARCH DESIGN AND METHODS: Biobanked serum from 4,957 ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial participants was analyzed. Forward-selection Cox models identified independent protein risk factors for major adverse cardiovascular events (MACE) and death that were compared with a previously validated biomarker panel.RESULTS: NT-proBNP and osteoprotegerin predicted both outcomes. In addition, trefoil factor 3 predicted MACE, and angiopoietin-2 predicted death (C = 0.70 and 0.79, respectively, compared with 0.63 and 0.66 for clinical variables alone). These proteins had all previously been identified and validated. Notably, C statistics for just NT-proBNP plus clinical risk factors were 0.69 and 0.78 for MACE and death, respectively.CONCLUSIONS: NT-proBNP and other proteins independently predict cardiovascular outcomes in people with type 2 diabetes following acute coronary syndrome. Adding other biomarkers only marginally increased NT-proBNP's prognostic value.

UR - http://www.scopus.com/inward/record.url?scp=85137138358&partnerID=8YFLogxK

U2 - 10.2337/dc22-0453

DO - 10.2337/dc22-0453

M3 - Journal article

C2 - 35817031

SN - 1935-5548

VL - 45

SP - 2152

EP - 2155

JO - Diabetes Care

JF - Diabetes Care

IS - 9

ER -

Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater